Company: ZVRA
Filing Date: 2025-03-13
Form Type: S-8
Source: 0001437749-25-007343
Chunk: 0

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-13
Form: S-8
Chunk 0
---
<div align='center'>As filed with the Securities and Exchange Commission on March 12 , 2025</div>

Registration No. 333-

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION
<div align='center'>WASHINGTON, D.C. 20549

FORM S-8</div>

### REGISTRATION STATEMENT
<div align='center'>UNDER

THE SECURITIES ACT OF 1933

Zevra Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)</div>

| Delaware                        |     | 20-5894398         |
| (State or Other Jurisdiction of 
 Incorporation or Organization)  |     | -I.R.S. Employer   
 Identification No. |

<div align='center'>1180 Celebration Boulevard, Suite103

Celebration, FL 34747

(Address of Principal Executive Offices) (Zip Code)

Zevra Therapeutics, Inc.

Amended and Restated 2014 Equity Incentive Plan

(Full Title of the Plan)

R. LaDuane Clifton, CPA

Chief Financial Officer and Treasurer

Zevra Therapeutics, Inc.

1180 Celebration Boulevard, Suite 103

Celebration, FL 34747

(Name and Address of Agent for Service)

(321) 939-3416

(Telephone Number, Including Area Code, of Agent for Service)

Copies to:</div>

| Nathan Ajiashvili, Esq.     
 Latham & Watkins LLP        
 1271 Avenue of the Americas 
 New York, NY 10020          
 (212) 906-1200              |

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant toSection 7(a)(2)(B) of the Securities Act. ☐

<div align='center'>2

Ex